vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Location
High Point, NC
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 937% % 42%
Debt-to-equity 70% % -57%
Return On Equity -74% % 21%
Return On Assets -44% % -7.3%
Operating Margin -175382% % -7209%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $22,364,235 USD -3.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $17,861,000 USD 55%
General and Administrative Expense $14,947,000 USD 9.5%
Operating Income (Loss) $32,808,000 USD -36%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $31,080,000 USD -37%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $26,974,000 USD -46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $88,932,000 USD 142%
Accounts Receivable, after Allowance for Credit Loss, Current $62,000 USD -39%
Other Assets, Current $218,000 USD 25%
Assets, Current $89,893,000 USD 136%
Property, Plant and Equipment, Net $14,000 USD -72%
Operating Lease, Right-of-Use Asset $24,000 USD -85%
Other Assets, Noncurrent $6,000 USD -96%
Assets $89,899,000 USD 135%
Accounts Payable, Current $1,132,000 USD 21%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $6,641,000 USD 28%
Contract with Customer, Liability, Noncurrent $18,669,000 USD 0%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $25,462,000 USD 6.2%
Retained Earnings (Accumulated Deficit) $326,692,000 USD -9%
Stockholders' Equity Attributable to Parent $64,437,000 USD 428%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $64,437,000 USD 351%
Liabilities and Equity $89,899,000 USD 135%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,687,000 USD 22%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,687,000 USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $88,932,000 USD 142%
Deferred Tax Assets, Valuation Allowance $50,128,000 USD 47%
Deferred Tax Assets, Gross $50,128,000 USD 47%
Operating Lease, Liability $125,000 USD -58%
Depreciation $9,000 USD -59%
Lessee, Operating Lease, Liability, to be Paid $129,000 USD -60%
Property, Plant and Equipment, Gross $536,000 USD -11%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.095 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,000 USD -76%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Deferred Tax Assets, Operating Loss Carryforwards $37,094,000 USD 33%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Share-based Payment Arrangement, Expense $3,775,000 USD 37%